Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

Tap Into Small-Cap Healthcare Opportunity With This ETF

BY | ETF Database
05/06/2025 | 153 VIEWS
In an extension of a long-running theme, biotechnology stocks are disappointing investors again in 2025. Large-cap gauges addressing the industry have performed mostly in line with the S&P 500. That’s nothing to write home about because that index has been lower since the start of the year. Not surprisingly, baskets of small-cap biotech equities have performed worse than large-cap equivalents.On the surface, that doesn’t provide market participants with much reason to consider small-cap healthcare stocks, particularly amid speculation that the U.S. economy is inching closer to a recession — a scenario that would likely plague small-cap names, regardless of sector. That outlook, while rooted in the facts of the current state of small-cap affairs, may belie opportunity with ETFs like the Invesco NASDAQ Future Gen 200 ETF (QQQS B+). QQQS, which follows the Nasdaq Innovators Completion Cap Index, isn’t a dedicated healthcare ETF, but it does it devote more than 48% of its roster to that sector, making it pertinent in the small-cap healthcare conversation.Biotech Still Hub of InnovationGiven the post-coronavirus vaccine lethargy encountered by many biotech equities, some investors may be thinking the industry, including QQQS holdings, lost its innovative ways. That’s not the case. In fact, biotech remains a hub of innovation — sentiment that applies to some of the group’s smaller companies, too. “There remains an abundance of innovation in the small-cap space, notably across the healthcare sector,” noted Vincent Nichols. “After all the genetic sequencing done over the last few years, some of the most impactful innovations will now likely come from translating that work into drugs over the next decade.” Even with an encouraging outlook for ongoing innovation among small-cap healthcare firms, active fund managers often overlook the space due to low market caps or perceptions regarding volatility. That could be a sign that, for risk-tolerant investors, QQQS is valid for consideration as a satellite holding. Additionally, QQQS could be at the right place at the right time if the Federal Reserve lowers interest rates. Not only would that help rate-sensitive small-cap biotech companies, it could finally spark a larger wave of consolidation in the healthcare sector — something investors have been waiting on for some time. “Healthcare mergers and acquisitions have picked up notably recently as large cash-rich pharmaceutical companies face patent cliffs and are looking to backfill drug pipelines. They often pay substantial takeout premiums,” added Nichols. “The combination of likely rate cuts by the Fed, boardroom optimism and a measure of economic stability could lead to more widespread vibrant M&A.” For more news, information, and analysis, visit the ETF Building Blocks Channel.

More Commentary

Put/Write ETF Could Gain Steam as Investors Embrace Options ETFs
BY | ETF Database
05/23/2025 | 69 VIEWS
Most Recent Tech Earnings Ease Anxiety Over AI Trade
BY | ETF Database
05/22/2025 | 43 VIEWS
In Ongoing Volatility, Look to Hedged Equity Strategies
BY | ETF Database
05/22/2025 | 62 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.